Genomic research is the key to unlocking a better understanding of clinical disease progression, leading to improved patient outcomes, and enhanced personalised care across diverse populations.
Advances in understanding of disease biology and major innovations in gene sequencing and data analysis has created a highly fertile scientific environment to support significant progress in the identification of genetic variants for non-alcoholic steatohepatitis (NASH).